Merck Millipore acquires rights for Biotest microbiology products
Merck Millipore now has exclusive rights to sell Biotest microbiology products in Australia and New Zealand.
In 2011, Merck Millipore acquired German company Biotest, an innovative industrial microbiology company with capabilities in ready-to-use media and hygiene monitoring. Its products are targeted at the pharmaceutical and food and beverage segments.
Biotest’s microbiology products, previously marketed by either of their two trading companies, Heipha and Hycon, are now exclusively available through Merck Millipore. Technical support for the products is also offered.
Noxopharm appoints Dr Olivier Laczka CEO
Australian clinical-stage biotech company Noxopharm Limited has appointed Dr Olivier Laczka as...
Nominations now open for the 2026 NMI Measurement Awards
Until 20 May, the National Measurement Institute (NMI) is accepting nominations for the 2026 NMI...
Australia to begin treaty negotiations on association to Horizon Europe
To give Australian organisations access to the world's largest pooled research fund in 2027,...
